Adjuvant bevacizumab for melanoma patients at high risk of recurrence: Survival analysis of the AVAST-M trial
No Thumbnail Available
Issue Date
2018
Our author(s)
Tahir, S.
Department
Keywords
Language
English
Publisher
Oxford University Press
ISSN
0923-7534
1569-8041
1569-8041
eISSN
ISBN
Type
Article
Citation
Corrie, P. G., Marshall, A., Nathan, P. D., Lorigan, P., Gore, M., Tahir, S., Faust, G., Kelly, C. G., Marples, M., Danson, S. J., Marshall, E., Houston, S. J., Board, R. E., Waterston, A. M., Nobes, J. P., Harries, M., Kumar, S., Goodman, A., Dalgleish, A., Martin-Clavijo, A., Westwell, S., Casasola, R., Chao, D., Maraveyas, A., Patel, P. M., Ottensmeier, C. H., Farrugia, D., Humphreys, A., Eccles, B., Young, G., Barker, E. O., Harman, C., Weiss, M., Myers, K. A., Chhabra, A., Rodwell, S. H., Dunn, J. A. & Middleton, M. R. 2018. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: Survival analysis of the AVAST-M trial. Annals of Oncology, 29, (8) 1843-1852.